Translate page

Perspectives on CML management

from Professor Jerry Radich
Fred Hutchinson Cancer Research Center
Seattle, USA

  • Assessment of existing therapies in CML including new data on bosunitib in front-line therapy
  • Emerging new therapies for CML and how they could come into practice
  • Perspectives on treatment discontinuation
  • Challenges of CML management in the emerging economic regions: access to treatment and testing

Highlights from EHA 2017:
2 CML experts give their personal perspectives

Perspectives on new CML studies from
Professor Timothy Hughes
South Australian Health and Medical Research Institute (SAHMRI), University of Adelaide, Royal Adelaide Hospital, Australia

  • Phase II study on dasatinib in children and adolescents with CML-CP
  • 10-year survival results of the German CML IV Study
  • Year 2 results from the British Destiny Study 
  • Initial results from the Before trial: Bosutinib vs. Imatinib in newly diagnosed CML
  • Update on treatment-free remission studies

 

Highlights from ASH 2016:
3 CML experts give their personal perspectives

This independent educational resource is supported by a grant from Novartis Oncology

Perspectives on molecular monitoring in CML from 
Associate Professor Susan Branford, PhD
Center for Cancer Biology
SA Pathology, Adelaide, Australia

  • Treatment-free remission studies including an update of the EURO-SKI trial
  • New data on optimal timing for monitoring patients after stopping therapy
  • Additional chromosomal abnormalities and their impact on prognosis
  • Next generation sequencing technologies 

Perspectives from Professor Jorge Cortes, MD

MD Anderson Cancer Center
University of Texas, Houston, USA

  • Different aspects on treatment discontinuation including 2nd treatment discontinuation and QoL assessment
  • Presentation of a new tyrosine kinase inhibitor
  • Generics making it into practice
  • Predictive markers and their impact on patients outcome
  • Considerations for treatment discontinuation in clinical practice including AE management

Perspectives on QoL assessment in CML patients from Dr Fabio Efficace, PhD 

Fondazione GIMEMA, Rome, Italy

Northwestern University, Feinberg School of Medicine, Chicago, USA

  • Importance of QoL assessment in CML
  • Correlation between QoL and adherence to therapy
  • Update on QoL data from the ENEST trials
  • Overview of measuring instruments to assess QoL and the importance of patient-related QoL measures

 

 

Keynote presentations from the recipients of the 2016 iCMLf Prizes

At the 18th Annual John Goldman Conference on CML in Houston the iCMLf Directors awarded the Foundation’s 2016 prize medals. This was followed by keynote presentations from the three prize winners. You can view web streams of the keynote presentations here.

Collage 2016 Keynotes Prizes

 

  • 2016 Rowley Prize: Professor Nora Heisterkamp 
  • 2016 Goldman Prize: Professor Hagop Kantarjian
  • 2016 iCMLf Prize: Associate Professor Susan Branford